Modern possibilities for the intensification of hypoglycemic therapy in the patients presenting with type 2 diabetes mellitus
https://doi.org/10.14341/probl201258649-52
Abstract
The results of the UKPDS study have demonstrated the importance of achieving an ideal level of glycemic control to guarantee the prevention or significant slowdown of the development of complications of diabetes mellitus (DM). However, a later study put in question the necessity of strict control in all the patients presenting with type 2 diabetes mellitus (DM2) because low HbA1c levels proved to be by no means always associated with the improvement of prognosis and even increased the risk of cardiovascular complications. Further investigations revealed the expediency of the treatment of diabetes mellitus on an individual basis with respect to both hypoglycemic therapy and formulation of its goals. The notion of safety of DM therapy acquired the primary significance. In this context, any novel approach ensuring the safety of treatment deserves serious attention. One such approach consists of taking advantage of the physiological benefits provided by the use of incretins that are intestinal hormones possessed of hypoglycemic activity. Our experience with the use of one of the DPP-4 inhibitors, vildagliptin, allows to recommend this preparation for the treatment of diabetic patients.
About the Authors
A. S. Ametov
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
F. T. Abaeva
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
References
1. Дедов И.И., Шестакова М.В. Сахарный диабет. М: Универсум Паблишинг 2003.
2. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2-го типа. М: ФГУ ЭНЦ 2010.
3. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabet Care 1998; 1414—1431.
4. UK Prospective Diabetes Study (UKPDS) Group.Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 9131: 837—853.
5. Аметов А.С. Уровень гликированного гемоглобина как значимый маркер полноценного гликемического контроля и предиктор поздних сосудистых осложнений сахарного диабета 2-го типа. РМЖ 2011; 19: 13: 407: 832—837.
6. Мамедов М.Н. Метформин от А до Я. Руководство для врачей. М 2008; 15—16.
7. Аметов А.С. Регуляция секреции инсулина в норме и при сахарном диабете 2-го типа: роль инкретинов. РМЖ 2006; 14: 26: 1867—1872.
8. Аметов А.С., Карпова Е.В. Инкретиномиметики – новый этап в лечении сахарного диабета 2-го типа. РМЖ 2010; 18: 23: 387: 1410—1415.
9. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Петунина Н.А., Сухарева О.Ю. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2-го типа». Сахарный диабет 2011; 1: 98—108.
10. Аметов А.С. Физиология метаболизма глюкозы. Сахарный диабет 2-го типа: проблемы и решения. РМЖ 2011; 21—51.
11. Аметов А.С., Иванова Е.В. Гипогликемия. Сахарный диабет 2-го типа: проблемы и решения. РМЖ 2011; 115—143.
12. Drucken D.J., Nauck M.A. The incretin system: glucagon–like peptide–1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696—1705.
13. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Phys Endocrinol Metab 2004; 287: E199—E206.
14. Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218—223.
15. Göke B., Hershon K., Kerr D., Calle Pascual A., Schweizer A., Foley J., Shao Q., Dejager S. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Department of Internal Medicine II, University of Munich-Grosshadern. Munich (Germany).
16. Ahrén B., Schweizer A., Dejager S., Dunning B.E., Nilsson P.M., Persson M., Foley J.E. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 4: 1236—1243.
Review
For citations:
Ametov A.S., Abaeva F.T. Modern possibilities for the intensification of hypoglycemic therapy in the patients presenting with type 2 diabetes mellitus. Problems of Endocrinology. 2012;58(6):49-52. (In Russ.) https://doi.org/10.14341/probl201258649-52
Views:
437
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
